Study of aversive and p38 mapk-inhibitory properties of kappa-agonist with analgesic activity - compound RU-1205

• Egile Nagusiak: Alexander A. Spasov (Egilea), Edwin E. Zvartau (Egilea), Olesya Iu. Grechko (Egilea), Natalya V. Eliseeva (Egilea), Yuliya V. Semenova (Egilea), Olga A. Dravolina (Egilea), Pavel M Vasiliev (Egilea), Vera A. Anisimova (Egilea)
• Formatua: Liburua
• Argitaratua: Belgorod National Research University, 2020-09-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Introduction: The clinical use of kappa-opioid agonists, despite their lack of significant drug potential, is limited by the development of severe sedation, dysphoria, depression, and anhedonia. To this date, there are kappa-opioid receptor agonists lacking these side effects due to the selective ac...